18 completed, 3 active not recruiting, 2 not yet recruiting, 1 terminated. 25 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 18, Active not recruiting 3, Not yet recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow HIV Seropositivity: new trials by email Literature Review of HIV Seropositivity trials Research Report on HIV Seropositivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma BrECADD - Hodgkin Lymphoma (Category) | Phase 2 | Not yet recruiting | University of Cologne | 35 | 2025-08-01 | 2025-04-09 |
| Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV Gammora® - HIV Seropositivity | Phase 2 | Active not recruiting | Federal University of São Paulo | 40 | 2025-01-01 | 2026-06-01 |
| Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy - ANCA-IgG-positive ANCA Associated Vasculitis | Phase 1 / Phase 2 | Not yet recruiting | David Simon | 8 | 2025-01-01 | 2024-09-19 |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome. Metformin Extended Release Oral Tablet - Metabolic Syndrome, HIV Seropositivity | Phase 2 | Completed | University of Stellenbosch | 30 | 2022-08-11 | 2025-10-06 |
| Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients CBD LGP 50, Placebo - HIV Seropositivity | Phase 2 | Completed | Centre Hospitalier Régional d'Orléans | 80 | 2022-05-16 | 2023-04-03 |
| Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia Gardasil 9 - Idiopathic CD4 T Cell Lymphocytopenia | Phase 2 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 54 | 2019-02-04 | 2026-10-29 |
| VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis - Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia | Phase 2 | Completed | AIDS Malignancy Consortium | 44 | 2018-09-21 | 2026-07-08 |
| Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Hepa-B, Engerix B - Hepatitis B Infection | Phase 2 / Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 158 | 2018-07-29 | 2022-02-11 |
| A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin - Kaposi's Sarcoma, HIV Positive | Phase 2 | Completed | ImmunityBio, Inc. | 15 | 2014-04-03 | 2024-06-11 |
| Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. HPV prophylactic vaccine Gardasil - Transplantation, Systemic Lupus Erythematosus | Phase 2 | Completed | University Hospital, Bordeaux | 37 | 2012-10-11 | 2026-05-20 |
| Chemotherapy for Lung Cancer in HIV-positive Patients Chemotherapy - Non-small Cell Lung Cancer, Hiv-positive | Phase 2 | Completed | Intergroupe Francophone de Cancerologie Thoracique | 61 | 2011-05-01 | 2023-03-14 |
| Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy Vorinostat - HIV Positive | Phase 2 | Unknown | Bayside Health | 20 | 2011-05-01 | 2017-04-25 |
| Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001) Multimeric-001, 500 mcg, Adjuvanted PBS, PBS and TIV 15% - Influenza | Phase 2 | Completed | BiondVax Pharmaceuticals ltd. | 200 | 2010-07-01 | 2012-07-31 |
| Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men Truvada - HIV Seroconversion, Stimulant Abuse | Phase 2 | Completed | Friends Research Institute, Inc. | 170 | 2010-05-01 | 2025-03-17 |
| Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma EPOCH-R, EPOCH-RR - Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive | Phase 2 | Completed | National Cancer Institute (NCI) | 194 | 2010-03-25 | 2023-04-27 |
| Lovastatin: Immunomodulatory Value Evaluation Lovastatin, placebo - HIV Seropositivity | Phase 2 | Completed | Universidad de Antioquia | 112 | 2008-08-01 | 2011-10-04 |
| Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+ ARV's + Placebo, Naltrexone, Naltrexone + ARV's - HIV Seropositivity | Phase 2 | Completed | The Ojai Foundation | 171 | 2008-03-01 | 2010-08-04 |
| Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy Atorvastatin, Placebo - HIV | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2006-10-18 | 2020-02-26 |
| A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. AGS-004 - HIV Seropositivity, Acquired Immunodeficiency Syndrome | Phase 1 / Phase 2 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 10 | 2006-09-01 | 2009-01-29 |
Showing 20 of 25. Sign in to see all of them.
HIV Infections (6) · Acquired Immunodeficiency Syndrome (3) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Diarrhea (1) · Hepatitis B (1) · Hodgkin Disease (1) · Influenza, Human (1) · Latent Tuberculosis (1) · Lupus Erythematosus, Systemic (1) · Lymphoma, Large B-Cell, Diffuse (1) · Metabolic Syndrome (1) · Neoplasms (1) · Opioid-Related Disorders (1)
Blood-Borne Infections (25) · Communicable Diseases (25) · Genital Diseases (25) · Immune System Diseases (25) · Immunologic Deficiency Syndromes (25) · Infections (25) · Lentivirus Infections (25) · RNA Virus Infections (25) · Retroviridae Infections (25) · Sexually Transmitted Diseases (25) · Sexually Transmitted Diseases, Viral (25) · Urogenital Diseases (25) · Virus Diseases (25) · HIV Infections (19) · DNA Virus Infections (3)
Tenofovir (3) · Emtricitabine (2) · poly(I).poly(c12,U) (2) · Atorvastatin (1) · Buprenorphine (1) · Case Management (1) · Cyclophosphamide (1) · Darunavir (1) · Diet Therapy (1) · Doxorubicin (1) · Drug Therapy (1) · Electroporation (1) · Electroporation Therapies (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Engerix-B (1)
AIM ImmunoTech Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · AIDS Malignancy Consortium (1) · Bayside Health (1) · BiondVax Pharmaceuticals ltd. (1) · Centers for Disease Control and Prevention (1) · Centre Hospitalier Régional d'Orléans (1) · Columbia University (1) · David Simon (1) · Federal University of São Paulo (1) · Friends Research Institute, Inc. (1) · ImmunityBio, Inc. (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Johns Hopkins University (1)
United States (11) · France (3) · South Africa (2) · Australia (1) · Bangladesh (1) · Brazil (1) · Canada (1) · Colombia (1) · Israel (1) · Mali (1) · Puerto Rico (1)
David R Strayer, MD (2) · Abdel K Traore, MD (1) · Andrea Lisco, M.D. (1) · Carlos J Montoya, MD, PhD (1) · Cathy J. Reback, Ph.D. (1) · Dr Vaneshree Govender (1) · Eric Decloedt, MBChB, PhD (1) · Fabian A Jaimes, MD, PhD (1) · Firdausi Qadri, PhD (1) · Frank Maldarelli, M.D. Ph.D. (1) · Gregory M Lucas, MD, PhD (1) · Jacob Atsmon, MD (1)
PMID 12631091, PMID 16800167, PMID 18528326, PMID 19538732, PMID 20513828, PMID 20949113, PMID 2161532, PMID 21859691, PMID 23085245, PMID 25393648, PMID 28301423, PMID 29201750, PMID 30501868, PMID 32291416, PMID 32444410, PMID 32453640, PMID 32855422, PMID 34347960, PMID 34501224, PMID 34561142, PMID 36109639, PMID 36927642, PMID 37748491, PMID 38182404, PMID 38381673
2025 (1), R21TW012185 (1), R29NR004169 (1), UM1CA121947 (1)